Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Gross Margin (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Gross Margin for 8 consecutive years, with 78.25% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 8018.0% to 78.25% in Q4 2025 year-over-year; TTM through Dec 2025 was 83.29%, a 3961.0% increase, with the full-year FY2025 number at 83.29%, up 2273.0% from a year prior.
  • Gross Margin was 78.25% for Q4 2025 at Akebia Therapeutics, down from 84.03% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 122.74% in Q3 2021 to a low of 29.44% in Q4 2021.
  • A 5-year average of 61.13% and a median of 75.15% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: skyrocketed 22504bps in 2021, then plummeted -8475bps in 2024.
  • Akebia Therapeutics' Gross Margin stood at 29.44% in 2021, then surged by 391bps to 85.77% in 2022, then dropped by -3bps to 82.82% in 2023, then tumbled by -102bps to 1.94% in 2024, then soared by 4142bps to 78.25% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Gross Margin are 78.25% (Q4 2025), 84.03% (Q3 2025), and 84.12% (Q2 2025).